Cargando…
The Breakthrough of Biosimilars: A Twist in the Narrative of Biological Therapy
The coming wave of patent expiries of first generation commercialized biotherapeutical drugs has seen the global market open its doors to close copies of these products. These near perfect substitutes, which are termed as “biosimilars”, do not need to undergo intense clinical trials for their approv...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770099/ https://www.ncbi.nlm.nih.gov/pubmed/31450637 http://dx.doi.org/10.3390/biom9090410 |